These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1827847)

  • 21. The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients.
    Flamm J; Spona J
    Int Urol Nephrol; 1988; 20(2):131-7. PubMed ID: 2968326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats.
    Rosenberg CA; Hrushesky WJ; Langevin T; Kennedy BJ
    Oncology; 1985; 42(1):48-54. PubMed ID: 3969257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
    Kjaer M
    Cancer Treat Rev; 1988 Sep; 15(3):195-209. PubMed ID: 2974757
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
    Zaccheo T; Giudici D; di Salle E
    Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 27. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.
    Rendina GM; Donadio C; Fabri M; Mazzoni P; Nazzicone P
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):285-91. PubMed ID: 6235140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
    Sylvester PW; Ip MM
    Prostate; 1987; 10(1):57-67. PubMed ID: 3822918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal testosterone concentration for the treatment of prostatic cancer.
    Trachtenberg J
    J Urol; 1985 May; 133(5):888-90. PubMed ID: 3989932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
    Johansson JE; Lingårdh G
    Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen inhibition of MPA-induced mouse mammary tumor transplants.
    Kordon E; Lanari C; Molinolo AA; Elizalde PV; Charreau EH; Dosne Pasqualini C
    Int J Cancer; 1991 Dec; 49(6):900-5. PubMed ID: 1835715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma.
    Damber JE; Landström M; Bergh A; Tomic R
    Scand J Urol Nephrol Suppl; 1988; 110():145-8. PubMed ID: 3187402
    [No Abstract]   [Full Text] [Related]  

  • 33. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.
    Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W
    Prostate; 1990; 16(4):313-23. PubMed ID: 2371176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental treatment of prostatic cancer by intermittent hormonal therapy.
    Trachtenberg J
    J Urol; 1987 Apr; 137(4):785-8. PubMed ID: 3560348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer.
    Ruff P; Derman DP; Weaving A; Bezwoda WR
    Oncology; 1989; 46(5):288-92. PubMed ID: 2528705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a best endocrine management of prostatic carcinoma?
    Robinson MR
    Prog Clin Biol Res; 1988; 269():147-58. PubMed ID: 2969114
    [No Abstract]   [Full Text] [Related]  

  • 37. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.
    Westin P; Brändström A; Damber JE; Bergh A
    Br J Cancer; 1995 Jul; 72(1):140-5. PubMed ID: 7599043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adriamycin action on human breast cancer cells: enhancement by medroxyprogesterone acetate.
    Shaikh NA; Owen AM; Ghilchik MW; Braunsberg H
    Int J Cancer; 1989 Apr; 43(4):733-6. PubMed ID: 2522913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.